Abstract
BackgroundAdalimumab (ADA) is approved for treatment of Crohn's disease (CD) and ulcerative colitis (UC); therefore, it is postulated that new onset or flare of inflammatory bowel disease (IBD) is a...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have